Metabolic syndrome at baseline was not predictive to new-onset cardiovascular diseases in patients with systemic lupus erythematosus: A prospective observational registry

Abstract

Objective: It has been established that metabolic syndrome is prevalent in patients with systemic lupus erythematosus (SLE). The objective of this study was to investigate the effect of metabolic syndrome at baseline on new-onset cardiovascular disease (CVD) in patients with SLE. Methods: The demographic and lupus-related clinical variables of 229 patients with SLE were collected from the Korean Lupus Network (KORNET) registry. Metabolic syndrome was defined by the modified National Cholesterol Education Program’s Adult Treatment Panel III (NCEP ATP III) criteria. Binary logistic regression analysis was applied to identify clinical variables including metabolic syndrome related to pre-existing CVD at the time of enrollment or new-onset CVD during 3 years of follow-up. Results: Patients with pre-existing CVD at baseline had higher rates of metabolic syndrome than those without CVD in SLE ( p = .022), whereas there was no difference in the frequency of metabolic syndrome between patients with and without new-onset CVD. Logistic regression analysis revealed that metabolic syndrome and the number of its components were associated with pre-existing CVD, together with body mass index and hypertriglyceridemia. Metabolic syndrome at baseline and its components were not related with increased risk of new-onset CVD. On the contrary, anti-dsDNA antibody titer, anti-ds DNA positivity, and lower diastolic blood pressure increased the risk of new-onset CVD. Conclusion: This study demonstrated that metabolic syndrome at baseline was not predictive to new-onset CVD at 3 years of follow-up, although it was associated with pre-existing CVD in SLE.